Hims & Hers Health has blazed a red-hot streak, helped by the growing popularity of weight-loss drugs. But after a massive ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

When asked whether we’ll ever find out who was behind the selloff, the CNBC TV show host stated: “Well no, and you never will ...

Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...

Hims & Hers Health (NYSE:HIMS – Free Report) had its price objective hoisted by Leerink Partners from $24.00 to $40.00 in a report published on Tuesday,Benzinga reports. They currently have a market ...

Eli Lilly and Company, Hims & Hers Health, UnitedHealth Group, Walmart, Tempus AI, Johnson & Johnson, and Merck & Co., Inc. are the seven Medical stocks to watch today, according to MarketBeat’s stock ...

Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...

Hims & Hers (NYSE: HIMS) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the ...

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...

We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Is your hair parting like the Red Sea? A few extra chunks of hair blocking the tub drain lately? Nobody wants to look for the ...